Mirum Pharmaceuticals, Inc. (MIRM)
100.90
+0.27
(+0.27%)
USD |
NASDAQ |
Sep 04, 16:00
100.85
-0.05
(-0.05%)
After-Hours: 20:00
Mirum Pharmaceuticals Research and Development Expense (Quarterly) : 90.29M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 90.29M |
| March 31, 2026 | 97.84M |
| December 31, 2025 | 51.03M |
| September 30, 2025 | 42.90M |
| June 30, 2025 | 45.91M |
| March 31, 2025 | 45.99M |
| December 31, 2024 | 43.97M |
| September 30, 2024 | 31.56M |
| June 30, 2024 | 32.52M |
| March 31, 2024 | 32.06M |
| December 31, 2023 | 30.84M |
| September 30, 2023 | 26.06M |
| June 30, 2023 | 21.97M |
| March 31, 2023 | 23.51M |
| December 31, 2022 | 31.00M |
| Date | Value |
|---|---|
| September 30, 2022 | 26.12M |
| June 30, 2022 | 25.33M |
| March 31, 2022 | 24.05M |
| December 31, 2021 | 27.69M |
| September 30, 2021 | 30.39M |
| June 30, 2021 | 34.97M |
| March 31, 2021 | 38.04M |
| December 31, 2020 | 29.64M |
| September 30, 2020 | 15.98M |
| June 30, 2020 | 18.56M |
| March 31, 2020 | 17.34M |
| December 31, 2019 | 14.38M |
| September 30, 2019 | 12.16M |
| June 30, 2019 | 11.59M |
| March 31, 2019 | 4.863M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Incyte Corp. | 497.47M |
| Insmed, Inc. | 210.03M |
| Praxis Precision Medicines, Inc. | 69.42M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |